Akut mieloid leukémia (AML): vizsgálatok itt: Kína
226 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisNot yet taking people in KínaA Phase III Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients
- Where
- Hangzhou
- Életkor
- 18 év and over
- People
- 318
- Run by
- Beijing InnoCare Pharma Tech Co., Ltd.
See details and how to joinNCT07925190 - 2. fázisTaking peopleInterferon-α Maintenance in Favorable-Risk AML
- Where
- Beijing
- Életkor
- 18 év to 70 év
- People
- 30
- Run by
- Peking University People's Hospital
See details and how to joinNCT07925554 - 1/2. fázisNot yet taking people in KínaPalbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
- Where
- Nanchang
- Életkor
- 18 év and over
- People
- 55
- Run by
- Second Affiliated Hospital of Nanchang University
See details and how to joinNCT07926607 - No phaseNot yet taking people in KínaRisk Stratification Value of Deep NGS-MRD Detection in Acute Myeloid Leukemia Patients After Allo-HSCT
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 169
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07919119 - No phaseNot yet taking people in KínaMAC vs RIC for Transplantation in FLT3-ITD-Mutated AML Guided by UHS-NGS MRD ( FLT3 - MAC vs RIC )
- Where
- Zhejiang
- Életkor
- 18 év to 60 év
- People
- 310
- Run by
- First Affiliated Hospital of Zhejiang University
See details and how to joinNCT07904884 - 3. fázisTaking peopleA Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Where
- Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Lanzhou, Nanchang, Nanjing, Nanning, Shenyang, Shenzhen, Suzhou, Tijian, Wenzhou, Wuhan, Xiamen, Xi'an, Zhengzhou
- Életkor
- 18 év and over
- People
- 600 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06852222 · EU 2024-520154-38-00 - 1. fázisTaking peoplePhase 1 Study of 6MW5311 in Adults With Relapsed or Refractory Blood Cancers
- Where
- Shanghai
- Életkor
- 18 év and over
- People
- 122
- Run by
- Mabwell (Shanghai) Bioscience Co., Ltd.
See details and how to joinNCT07914556 - 1/2. fázisNot yet taking people in KínaMulti-CAR T Cell Therapy for Acute Myeloid Leukemia
- Where
- Shenzhen
- Életkor
- 2 év to 75 év
- People
- 10
- Run by
- Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT03222674 - 1/2. fázisNot yet taking people in KínaMulti-CAR T Cell Therapy Targeting CD7-positive Malignancies
- Where
- Shenzhen
- Életkor
- 6 hónap to 75 év
- People
- 30
- Run by
- Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT04033302 - 1. fázisNot yet taking people in KínaUniversal 4SCAR7U Targeting CD7-positive Malignancies
- Where
- Shenzhen
- Életkor
- 6 hónap to 75 év
- People
- 30
- Run by
- Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT05995028 - 1. fázisNot yet taking people in KínaUniversal CAR-T Cells Targeting AML
- Where
- Shenzhen
- Életkor
- 6 hónap to 75 év
- People
- 30
- Run by
- Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT05995041 - 1. fázisNot yet taking people in KínaCLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 12
- Run by
- Liping Dou
See details and how to joinNCT07897136 - 3. fázisTaking peopleComparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
- Where
- Tianjin
- Életkor
- 55 év to 75 év
- People
- 228
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07132684 - 3. fázisTaking peopleAzacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML
- Where
- Tianjin
- Életkor
- 14 év to 75 év
- People
- 788
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07539818 - 1. fázisTaking peopleClinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia
- Where
- Hangzhou
- Életkor
- 18 év and over
- People
- 36
- Run by
- Hangzhou Weben Pharma Co., Ltd
See details and how to joinNCT07014449 - 1. fázisTaking peoplePhase I Study of FXS0683 in the Treatment of Blood Tumors
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 228
- Run by
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
See details and how to joinNCT07616089 - 2. fázisTaking peopleVenetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
- Where
- Beijing
- Életkor
- 18 év and over
- People
- 50
- Run by
- Beijing 302 Hospital
See details and how to joinNCT07078591 - 1. fázisNot yet taking people in KínaCLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia
- Where
- Beijing
- Életkor
- 18 év to 75 év
- People
- 12
- Run by
- Liping Dou
See details and how to joinNCT07841002 - 1. fázisTaking peopleA Study of XS-04 in Patients With Relapsed or Refractory Hematologic Malignancies
- Where
- Beijing, Guangdong, Hebei, Hubei
- Életkor
- 18 év to 75 év
- People
- 168
- Run by
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
See details and how to joinNCT06820268 - 2. fázisTaking peopleEvaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- Where
- Beijing, Changchun, Guangzhou, Hangzhou, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Suzhou, Tianjin, Wenzhou, Xiamen, Xi'an, Xuzhou, Zhengzhou
- Életkor
- 18 év and over
- People
- 130 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06824168 - 1/2. fázisTaking peopleA Study of BGB-11417 in Participants With Myeloid Malignancies
- Where
- Beijing, Chengdu, Guangzhou, Hangzhou, Lanzhou, Nanchang, Shenzhen, Suzhou, Tianjin, Wuhan, Zhengzhou
- Életkor
- 18 év and over
- People
- 260 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT04771130 · EU 2023-508881-14-00 - 1. fázisTaking peopleA Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMML
- Where
- Nanchang, Suzhou, Zhengzhou
- Életkor
- 18 év and over
- People
- 198
- Run by
- Guangzhou Lupeng Pharmaceutical Company LTD.
See details and how to joinNCT05641259 - Korai 1. fázisNot yet taking people in KínaA Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Where
- Shenzhen
- Életkor
- 18 év to 75 év
- People
- 36
- Run by
- Grit Biotechnology
See details and how to joinNCT07676006 - 2/3. fázisTaking peopleA Study of BL-M11D1 in Combination With Cytarabine + Daunorubicin or Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
- Where
- Tianjin
- Életkor
- 18 év to 75 év
- People
- 216
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT07255872 - 2. fázisCsak meghívásosHomoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure
- Where
- Guangzhou
- Életkor
- 18 év and over
- People
- 73
- Run by
- Guangdong Second Provincial General Hospital
See details and how to joinNCT07813390